Skip to main content

Table 9 USA hCG Reference Service experience, concentration of hCG, hyperglycosylated hCG and hyperglycosylated hCG free β (HhCG β) in serum samples in gestational trophoblastic diseases and non-gestational malignancies.

From: New discoveries on the biology and detection of human chorionic gonadotropin

Source

n

Total hCG mIU/ml median (range)

hCG-H mIU/ml molar1 % total hCG ± SD?

HhCGβ mIU/ml molar1 % total hCG ± SD

Complete hydatidiform mole

(prior to evacuation)

30

192,995

(24160 – 3704084)

4.9 ± 2.1%

7.1 ± 20%3

Partial hydatidiform mole

(prior to evacuation)

21

48,900

(11600 – 220114)

3.6 ± 1.7%

5.8 ± 22%3

Invasive mole, recurrent mole

(at commencement of therapy)

72

869

(24 – 30255)

30 ± 35%

7.7 ± 11%

PSTT

(at time of diagnosis)2

21

30

(1 – 231)

7.1 ± 13%

61 ± 21%

Highly invasive Choriocarcinoma

> 50% hyperglycosylated hCG2

17

45,350

(3,020 – 596,600)

98 ± 5%

7.8 ± 8.4%

Invasive Choriocarcionoma

< 50% hyperglycosylated hCG

44

4,258

(108 – 10,245)

32 ± 11%

6.4 ± 7.5%

Quiescent GTD

(at time of diagnosis)2

93

22

(1 – 212)

0.10% ± 0.72%

2.7 ± 8.4%

Other gynecologic malignancies

(at time of diagnosis)2

14

33

(0.5 – 474)

0.55 ± 1.3%

91 ± 11%

  1. SD is standard deviation. Choriocarcinoma cases are those with and without histology (GTN).
  2. 1Values are measured in molar units and converted to equivalents of hCG, assuming that 1 ng/ml hCG is 11 mIU/ml (using hCG 1st RR standard).
  3. 2As measured by USA hCG Reference Service, indicated diagnosis confirmed at biopsy by referring center
  4. 3 As published by Van Trommel et al. (45).